"CardioNova", Ltd is a private biotechnology company, founded in 2011 to develop and launch into the Russian market innovative products to treat cardiovascular disease. Since December 2011 “CardioNova” has become a resident of Skolkovo Biomed Cluster.

The first product (AHRO-001) is aimed at treatment and prevention of atherosclerosis dysplipidemia and developed in the framework of international cooperation with public biotech company AtheroNova, Inc. (OTC: AHRO).

In 2011, experiments on the effectiveness were conducted in preclinical murine models, as a result the therapeutic effect of the drug was shown, as well as its ability to reduce the size of atherosclerotic vessels. Subsequently assumed to assess safety of the drug designed to obtain authorization to conduct clinical research.


Search form